One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Discover OPKO Health's Q2 2025 earnings insights, highlighting asset sales, cost savings, and pipeline advancements.

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

By the end of 2024, Axmed had partnered with over 20 organizations across 15 countries. It processed more than 4,200 orders, ...

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...

With Virgin shares holding nicely at cruising altitude, is now the right time for private oncology drug developer Qbiotics to ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen ...

On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday ...

Like other IPO candidates – and the list is growing – private oncology drug developer Qbiotics has been closely watching the ...

Promising Ewing Sarcoma Pipeline Therapies such as Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.